Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M

Immunovant, Inc.

2026-Q2 EPS reported -$1.43

Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.
Cash and equivalents $521.9M providing runway through GD readout expected in 2027.
Batoclimab Phase 3 TED: first readout delayed; both studies now expected to report concurrently H1 2026.
IMVT-1402 GD study showed first-ever potentially disease-modifying therapy with 6-month off-treatment data.
Topline results for IMVT-1402 in D2T RA and CLE expected 2026; GD, MG, D2T RA in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.